Compare · GILD vs IAM

GILD vs IAM

Side-by-side comparison of Gilead Sciences Inc. (GILD) and Iambic Therapeutics Inc. (IAM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both GILD and IAM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $206.55B, about 305.6x IAM ($675.9M).
  • GILD has been more active in the news (22 items in the past 4 weeks vs 10 for IAM).
  • GILD has more recent analyst coverage (25 ratings vs 4 for IAM).
MetricGILDIAM
Company
Gilead Sciences Inc.
Iambic Therapeutics Inc.
Price
-
-
Market cap
$206.55B
$675.9M
1M return
+8.45%
-
1Y return
+33.25%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
1992
2026
News (4w)
22
10
Recent ratings
25
4
GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

IAM

Iambic Therapeutics Inc.

Iambic's mission is to make better technology for better medicines. By utilizing molecular superintelligence - integrating proprietary AI with automated, scalable chemistry and biology experimentation - our platform is designed to address the totality of drug discovery and development. We believe the utility of our platform is demonstrated by the discovery of IAM1363, a novel drug candidate advanced to clinic in approximately two years, along with a diverse preclinical pipeline. Our leading AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction designed to improve the speed, precision, and success rates of drug discovery and clinical development. At Iambic, we are building an engine that is designed to power the future of medicine.

Latest GILD

Latest IAM